2025 Q4 -tulosraportti
48 päivää sitten
‧23 min
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 222 | - | - | ||
| 778 | - | - | ||
| 2 | - | - | ||
| 58 | - | - | ||
| 800 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 18.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sitten@M: You no longer contribute critical analyses – you spew out claims that don't withstand a simple fact-check. This is an investor forum!!!! Not a stage for spreading misinformation disguised as "skepticism"! Serious investors want both bull and bear, but that presupposes that the arguments are rooted in facts. When your posts repeatedly turn out to be directly wrong or misleading, it becomes difficult to interpret it as anything other than either gross incompetence or deliberate deception. Both are equally useless in a serious discussion. So an honest question: what is actually your goal here??!?!- ·2 päivää sitten · Muokattu@M: I've actually stopped responding to your meaningless claims, but sometimes your posts are so thoroughly misleading that they not only spread disinformation, but pure deception – and then they must be answered! When your claims can be fact-checked in 10 seconds, yet are presented with absolute certainty, one might question your mental health status! Especially after your latest outburst, one also begins to wonder if this is actually driven by some kind of hateful agenda against the company, more than a desire to contribute facts. Your claim: “At Cowen's investor conference recently, VP-315 was not mentioned with a single word by Verrica..." Fact check: Based on the transcript from the TD Cowen 46th Annual Health Care Conference, VP-315 was both explicitly mentioned and actively discussed. This is not a gray area or interpretation, but it is a direct lie! https://www.investing.com/news/transcripts/verrica-pharmaceuticals-at-td-cowen-conference-strategic-insights-93CH-4535869·2 päivää sitten · MuokattuImpressive level: a large percentage of your claims that are fact-checked end up with labels like “lie”, “misinterpretation” or “not entirely correct”. Either you have discovered a worldwide conspiracy – or you are consistently wrong!
·25.3.So Verrica is also sued. https://www.ainvest.com/news/verrica-faces-legal-catalyst-mispriced-short-squeeze-setup-2603/
·2 päivää sittenIt's probably rather the other way around: Verrica would never have entered into a deal with Lytix if they had the choice again. The deal was good for Lytix, but bad for Verrica. Verrica's shareholders will not waste more money on bringing VP315 to market, and consequently, development has been halted until a partner expresses interest in taking over for Verrica. This is despite Verrica having received a very simple and cheap Phase 3 from the FDA, yet they will not put one more krone into it. The previous CEO (Ted White) who entered into the Lytix agreement and spent large sums on Phase 2 was fired. At Cowen's investor conference recently, VP315 was not mentioned by Verrica at all. It is very quiet around it, so it is clear Verrica is downplaying this misstep and wants most focus on the other assets in its pipeline. Short interest is high and Verrica's stock price is sharply falling. Lytix uses every opportunity to conduct new share issues going forward, and advertises with full-page ads in Kapital and Finansavisen constantly in an attempt to attract interest from new fresh money. Hundreds of millions in additional cash are still needed here. Do you think a partner who will get Verrica out of this predicament with VP315 is right around the corner? You do the math....
·25.3.No hyping from my side, but: "Merck braces for Keytruda patent loss with $6.7 billion Terns bet" https://www.reuters.com/business/healthcare-pharmaceuticals/merck-boosts-cancer-portfolio-with-67-billion-buyout-terns-pharma-2026-03-25/ "[Keytruda] [...] generated more than $30 billion in 2025" Semi-relevant for Lytix, perhaps? NeoLIPA An investigator-initiated Phase 2 study with ruxotemitide is currently underway at the Oslo University Hospital. This study is exploring neo-adjuvant ruxotemitide (administered before surgery) in combination with standard of care pembrolizumab (KEYTRUDAⓇ) in patients with resectable melanoma. The objective of this study is to demonstrate that ruxotemtidie improves outcomes in these patients and prevents disease recurrence.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
48 päivää sitten
‧23 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sitten@M: You no longer contribute critical analyses – you spew out claims that don't withstand a simple fact-check. This is an investor forum!!!! Not a stage for spreading misinformation disguised as "skepticism"! Serious investors want both bull and bear, but that presupposes that the arguments are rooted in facts. When your posts repeatedly turn out to be directly wrong or misleading, it becomes difficult to interpret it as anything other than either gross incompetence or deliberate deception. Both are equally useless in a serious discussion. So an honest question: what is actually your goal here??!?!
- ·2 päivää sitten · Muokattu@M: I've actually stopped responding to your meaningless claims, but sometimes your posts are so thoroughly misleading that they not only spread disinformation, but pure deception – and then they must be answered! When your claims can be fact-checked in 10 seconds, yet are presented with absolute certainty, one might question your mental health status! Especially after your latest outburst, one also begins to wonder if this is actually driven by some kind of hateful agenda against the company, more than a desire to contribute facts. Your claim: “At Cowen's investor conference recently, VP-315 was not mentioned with a single word by Verrica..." Fact check: Based on the transcript from the TD Cowen 46th Annual Health Care Conference, VP-315 was both explicitly mentioned and actively discussed. This is not a gray area or interpretation, but it is a direct lie! https://www.investing.com/news/transcripts/verrica-pharmaceuticals-at-td-cowen-conference-strategic-insights-93CH-4535869·2 päivää sitten · MuokattuImpressive level: a large percentage of your claims that are fact-checked end up with labels like “lie”, “misinterpretation” or “not entirely correct”. Either you have discovered a worldwide conspiracy – or you are consistently wrong!
- ·25.3.So Verrica is also sued. https://www.ainvest.com/news/verrica-faces-legal-catalyst-mispriced-short-squeeze-setup-2603/·2 päivää sittenIt's probably rather the other way around: Verrica would never have entered into a deal with Lytix if they had the choice again. The deal was good for Lytix, but bad for Verrica. Verrica's shareholders will not waste more money on bringing VP315 to market, and consequently, development has been halted until a partner expresses interest in taking over for Verrica. This is despite Verrica having received a very simple and cheap Phase 3 from the FDA, yet they will not put one more krone into it. The previous CEO (Ted White) who entered into the Lytix agreement and spent large sums on Phase 2 was fired. At Cowen's investor conference recently, VP315 was not mentioned by Verrica at all. It is very quiet around it, so it is clear Verrica is downplaying this misstep and wants most focus on the other assets in its pipeline. Short interest is high and Verrica's stock price is sharply falling. Lytix uses every opportunity to conduct new share issues going forward, and advertises with full-page ads in Kapital and Finansavisen constantly in an attempt to attract interest from new fresh money. Hundreds of millions in additional cash are still needed here. Do you think a partner who will get Verrica out of this predicament with VP315 is right around the corner? You do the math....
- ·25.3.No hyping from my side, but: "Merck braces for Keytruda patent loss with $6.7 billion Terns bet" https://www.reuters.com/business/healthcare-pharmaceuticals/merck-boosts-cancer-portfolio-with-67-billion-buyout-terns-pharma-2026-03-25/ "[Keytruda] [...] generated more than $30 billion in 2025" Semi-relevant for Lytix, perhaps? NeoLIPA An investigator-initiated Phase 2 study with ruxotemitide is currently underway at the Oslo University Hospital. This study is exploring neo-adjuvant ruxotemitide (administered before surgery) in combination with standard of care pembrolizumab (KEYTRUDAⓇ) in patients with resectable melanoma. The objective of this study is to demonstrate that ruxotemtidie improves outcomes in these patients and prevents disease recurrence.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 222 | - | - | ||
| 778 | - | - | ||
| 2 | - | - | ||
| 58 | - | - | ||
| 800 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 18.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
2025 Q4 -tulosraportti
48 päivää sitten
‧23 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 18.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sitten@M: You no longer contribute critical analyses – you spew out claims that don't withstand a simple fact-check. This is an investor forum!!!! Not a stage for spreading misinformation disguised as "skepticism"! Serious investors want both bull and bear, but that presupposes that the arguments are rooted in facts. When your posts repeatedly turn out to be directly wrong or misleading, it becomes difficult to interpret it as anything other than either gross incompetence or deliberate deception. Both are equally useless in a serious discussion. So an honest question: what is actually your goal here??!?!
- ·2 päivää sitten · Muokattu@M: I've actually stopped responding to your meaningless claims, but sometimes your posts are so thoroughly misleading that they not only spread disinformation, but pure deception – and then they must be answered! When your claims can be fact-checked in 10 seconds, yet are presented with absolute certainty, one might question your mental health status! Especially after your latest outburst, one also begins to wonder if this is actually driven by some kind of hateful agenda against the company, more than a desire to contribute facts. Your claim: “At Cowen's investor conference recently, VP-315 was not mentioned with a single word by Verrica..." Fact check: Based on the transcript from the TD Cowen 46th Annual Health Care Conference, VP-315 was both explicitly mentioned and actively discussed. This is not a gray area or interpretation, but it is a direct lie! https://www.investing.com/news/transcripts/verrica-pharmaceuticals-at-td-cowen-conference-strategic-insights-93CH-4535869·2 päivää sitten · MuokattuImpressive level: a large percentage of your claims that are fact-checked end up with labels like “lie”, “misinterpretation” or “not entirely correct”. Either you have discovered a worldwide conspiracy – or you are consistently wrong!
- ·25.3.So Verrica is also sued. https://www.ainvest.com/news/verrica-faces-legal-catalyst-mispriced-short-squeeze-setup-2603/·2 päivää sittenIt's probably rather the other way around: Verrica would never have entered into a deal with Lytix if they had the choice again. The deal was good for Lytix, but bad for Verrica. Verrica's shareholders will not waste more money on bringing VP315 to market, and consequently, development has been halted until a partner expresses interest in taking over for Verrica. This is despite Verrica having received a very simple and cheap Phase 3 from the FDA, yet they will not put one more krone into it. The previous CEO (Ted White) who entered into the Lytix agreement and spent large sums on Phase 2 was fired. At Cowen's investor conference recently, VP315 was not mentioned by Verrica at all. It is very quiet around it, so it is clear Verrica is downplaying this misstep and wants most focus on the other assets in its pipeline. Short interest is high and Verrica's stock price is sharply falling. Lytix uses every opportunity to conduct new share issues going forward, and advertises with full-page ads in Kapital and Finansavisen constantly in an attempt to attract interest from new fresh money. Hundreds of millions in additional cash are still needed here. Do you think a partner who will get Verrica out of this predicament with VP315 is right around the corner? You do the math....
- ·25.3.No hyping from my side, but: "Merck braces for Keytruda patent loss with $6.7 billion Terns bet" https://www.reuters.com/business/healthcare-pharmaceuticals/merck-boosts-cancer-portfolio-with-67-billion-buyout-terns-pharma-2026-03-25/ "[Keytruda] [...] generated more than $30 billion in 2025" Semi-relevant for Lytix, perhaps? NeoLIPA An investigator-initiated Phase 2 study with ruxotemitide is currently underway at the Oslo University Hospital. This study is exploring neo-adjuvant ruxotemitide (administered before surgery) in combination with standard of care pembrolizumab (KEYTRUDAⓇ) in patients with resectable melanoma. The objective of this study is to demonstrate that ruxotemtidie improves outcomes in these patients and prevents disease recurrence.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 222 | - | - | ||
| 778 | - | - | ||
| 2 | - | - | ||
| 58 | - | - | ||
| 800 | - | - |
Välittäjätilasto
Dataa ei löytynyt